Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The present amplification via primer ligation at the mutation (APRIL-ATM) has potential applications in the detection of mutagen-generated genetic alterations, early detection of tumor marker mutations in bodily discharges and the diagnosis of minimal residual disease.
|
12202623 |
2002 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor growth-promoting as well as apoptosis-inducing effects of APRIL have been described.
|
11550092 |
2001 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
APRIL was observed near Ki67(+) nuclei and was distributed heterogeneously in the cancer cells, in the leukocyte infiltrate, and in the myoepithelial layer adjacent to the tumor area; these results imply that APRIL provides proliferation signals to tumor cells through paracrine and autocrine signaling.
|
25750171 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, our results showed that chemokine-mediated recruitment of neutrophils secreting the tumor-promoting factor APRIL mediates DLBCL progression.<i></i>.
|
27923834 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It was shown that NFkB activation in MM tumors results mainly from extrinsic signaling by APRIL and BAFF ligands that stimulate receptors on normal plasma cells as well as on pre-malignant monoclonal gammopathy of undetermined significance (MGUS) and MM tumors.
|
20890394 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, APRIL-transfected NIH-3T3 cells show an increased rate of tumor growth in nude mice compared with the parental cell line.
|
9743536 |
1998 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We detected significantly increased APRIL levels in sera of B cell chronic lymphoid leukemia (B-CLL) patients, indicating that APRIL promotes onset of B-1-associated neoplasms and that APRIL antagonism may provide a therapeutic strategy to treat B-CLL patients.
|
15488762 |
2004 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
APRIL can stimulate tumor cell growth and is up-expressed in cancer tissues, especially in CRC (colorectal cancer).
|
24771268 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, whereas interaction of APRIL with HSPG does not influence APRIL-induced proliferation of T cells, it is crucial for its tumor growth-promoting activities.
|
15846369 |
2005 |
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
APRIL and BAFF are involved in a variety of tumor and autoimmune diseases, including B-cell malignancies.
|
15070697 |
2004 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Stratified analysis revealed that protein expression of APRIL in the tumour stroma is associated with survival in adjuvant 5FU treated patients only (n = 103, p < 0.001), and is independently predictive of lack of clinical benefit from adjuvant 5FU [HR 6.25 (95%CI 1.48-26.32), p = 0.013].
|
20003335 |
2009 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also found overexpression of at least one proteoglycan with heparan sulfate chains (HS), which are coreceptors for APRIL and TACI, in tumors where APRIL is either overexpressed or is a prognostic factor.
|
19291294 |
2009 |